Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232154 · ClinicalTrials.gov registry record · Phase 2
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
A Phase 2 study of Sinusitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 18
- Study locations
NCT00232154: Completed Phase 2 study of Sinusitis, sponsored by Pfizer.
NCT00232154 is a Phase 2 study of Sinusitis that has completed, run by Pfizer. The registered enrollment target is 72 participants, below the 125-participant average among 12 other Sinusitis trials with a reported enrollment target (42% lower). The trial reports 18 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232154, a Phase 2 study of Sinusitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 18
- Study locations
Study Summary
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
Conditions Studied
Interventions
- DRUG Zithromax™ (azithromycin) 500mg tablets
- PROCEDURE Endoscopic Sinus Surgery
- PROCEDURE Blood sampling for hematology
- PROCEDURE Blood sampling for plasma chemistry profile
- PROCEDURE Serum pregnancy test (for women of child-bearing potential)
Study Locations (18)
Alabama
- Pfizer Investigational Site - Alabaster
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Hoover
- Pfizer Investigational Site - Hoover
Illinois
- Pfizer Investigational Site - Elgin
- Pfizer Investigational Site - Elgin
- Pfizer Investigational Site - Maywood
Kentucky
- Pfizer Investigational Site - Carrollton
- Pfizer Investigational Site - La Grange
- Pfizer Investigational Site - Louisville
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Miami
California
- Pfizer Investigational Site - Fresno
Georgia
- Pfizer Investigational Site - Augusta
North Carolina
- Pfizer Investigational Site - Durham
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00232154 record still lists
NCT00232154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 125-participant average among 12 other Sinusitis trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Sinusitis appearing as the primary indexed condition, and to 5 interventions - of which Zithromax™ (azithromycin) 500mg tablets is the first listed.
NCT00232154 lists 18 locations in 8 states (Alabama, Illinois, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00232154 about?
NCT00232154 is a clinical study titled "A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To". To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
What is the current status of trial NCT00232154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-11. Estimated completion is 2006-06.
What conditions does trial NCT00232154 study?
This clinical trial studies the following conditions: Sinusitis.
What interventions are being tested in trial NCT00232154?
The interventions under investigation include: Zithromax™ (azithromycin) 500mg tablets (DRUG), Endoscopic Sinus Surgery (PROCEDURE), Blood sampling for hematology (PROCEDURE), Blood sampling for plasma chemistry profile (PROCEDURE), Serum pregnancy test (for women of child-bearing potential) (PROCEDURE).
Who is sponsoring clinical trial NCT00232154?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232154 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sinusitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00232154's enrollment target sits among peer trials
72 5th of 12 higher than 8 of 12 other Sinusitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sinusitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
COMPLETED · Phase 2
-
How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.
RECRUITING · NA
-
High Resolution Micro OCT Imaging
ACTIVE NOT RECRUITING
-
Dupixent Study for Alternate Administration
ACTIVE NOT RECRUITING · Phase 4
-
Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care
ACTIVE NOT RECRUITING
-
Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia